Understanding PML nuclear bodies disruption in the context of AML treatment
A better understanding of the onset and development of acute myeloid leukaemia (AML) may lead to new therapeutic strategies. Acute promyelocytic leukaemia (APL), a subset of AML, can be successfully cured by combination therapy. Therefore, understanding the mechanisms underlying the pathogenesis and successful treatment of APL will improve the management of AML subsets with a poor prognosis. Promyelocytic leukaemia nuclear bodies (PML NBs), an archetype of membrane-less organelles that concentrate proteins at discrete sites within the nucleoplasm, are essential for APL pathogenesis and treatment response. The EU-funded PMLingAML project will elucidate the mechanisms of PML NBs disruption in APL, aiming to apply this knowledge in the treatment of other AML subsets.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF-EF-ST - Standard EF
See on map